Upstream Bio, Stock Current Valuation
UPB Stock | 19.19 0.26 1.34% |
Valuation analysis of Upstream Bio, helps investors to measure Upstream Bio,'s intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Upstream Bio,'s Change In Cash is projected to increase significantly based on the last few years of reporting. The current year's Begin Period Cash Flow is expected to grow to about 17.3 M, whereas Cash is forecasted to decline to about 23.6 M.
Undervalued
Today
Please note that Upstream Bio,'s price fluctuation is somewhat reliable at this time. Calculation of the real value of Upstream Bio, is based on 3 months time horizon. Increasing Upstream Bio,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Upstream Bio, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Upstream Stock. However, Upstream Bio,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. Historical | Market 19.19 | Real 20.68 | Hype 20.04 |
The real value of Upstream Stock, also known as its intrinsic value, is the underlying worth of Upstream Bio, Company, which is reflected in its stock price. It is based on Upstream Bio,'s financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Upstream Bio,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Upstream Bio, helps investors to forecast how Upstream stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Upstream Bio, more accurately as focusing exclusively on Upstream Bio,'s fundamentals will not take into account other important factors: Upstream Bio, Company Current Valuation Analysis
Upstream Bio,'s Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Upstream Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Upstream Bio, is extremely important. It helps to project a fair market value of Upstream Stock properly, considering its historical fundamentals such as Current Valuation. Since Upstream Bio,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Upstream Bio,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Upstream Bio,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition |
In accordance with the recently published financial statements, Upstream Bio, has a Current Valuation of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
Upstream Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Upstream Bio,'s direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Upstream Bio, could also be used in its relative valuation, which is a method of valuing Upstream Bio, by comparing valuation metrics of similar companies.Upstream Bio, is currently under evaluation in current valuation category among its peers.
About Upstream Bio, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Upstream Bio,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Upstream Bio, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Upstream Bio, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Upstream Bio, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Upstream Bio,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Upstream Bio, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Upstream Bio, Stock:Check out Upstream Bio, Piotroski F Score and Upstream Bio, Altman Z Score analysis. For information on how to trade Upstream Stock refer to our How to Trade Upstream Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Upstream Bio,. If investors know Upstream will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Upstream Bio, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Upstream Bio, is measured differently than its book value, which is the value of Upstream that is recorded on the company's balance sheet. Investors also form their own opinion of Upstream Bio,'s value that differs from its market value or its book value, called intrinsic value, which is Upstream Bio,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Upstream Bio,'s market value can be influenced by many factors that don't directly affect Upstream Bio,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Upstream Bio,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Upstream Bio, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Upstream Bio,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.